Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Maruishi Takes Over Bayer’s Sleep Inducer Evamyl in Japan
June 17, 2025
- Mitsubishi’s BRD4 Degrader Now in US PI/II for Solid Tumors
June 16, 2025
- Sumitomo’s Myelofibrosis Drug Earns Fast-Track Tag in US
June 16, 2025
- Novartis Makes Full Foray into Nephrology Space with Fabhalta: Exec
June 16, 2025
- Japan Vaccine Market to Reach 297 Billion Yen in FY2025: Fuji Keizai
June 13, 2025
- SanBio Inches Closer to Cell Therapy Shipment with Partial Change Filing
June 13, 2025
- Nippon Chemiphar to Launch Amaryl AGs on June 20
June 13, 2025
- Takeda’s Livmarli, HyQvia Now Available in Japan
June 13, 2025
- Boehringer Files Nerandomilast for Pulmonary Fibrosis in Japan
June 13, 2025
- Pfizer Pushes Back Champix Re-Supply Plan on Regulatory Delay
June 12, 2025
- AbbVie Japan Looks to Double Sales by 2029 with Rinvoq and Skyrizi as Engines
June 12, 2025
- Prashant Nikam to Take Over Helm of MSD Japan
June 12, 2025
- Takeda Seeks Japan Nod for Vonvendi Use in Patients Under 18
June 11, 2025
- Enhertu Enters PIII for 1st-Line Endometrial Cancer Use: Daiichi
June 11, 2025
- Taking on Solid Tumors - 5: Genmab Pursuing Unique T-Cell Engager Program for Lung Cancer
June 11, 2025
- Taking on Solid Tumors - 4: With 2 Late-Stage Assets in Wings, Will AstraZeneca Reshape CP Inhibitor Landscape?
June 10, 2025
- SSP Files for OTC Switch of Tadalafil in Japan
June 10, 2025
- Nipro, Samsung Bioepis Tie Up on Biosimilar Business in Japan
June 10, 2025
- Sawai Follows Fuso to Challenge Remitch Patent Ruling
June 10, 2025
- Otsuka’s Sibeprenlimab Scores Positive Results in PIII: Interim Analysis
June 9, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…